slides · global inventory
Callout
Component collection for the active corpus filters, with each row opening the slide detail view.
Matching slides 41,369
Current window 34,891-34,920
Pages 1,379
Rows per page 30
Component
34,891-34,920 of 41,369
16
The slide uses a split-screen layout with a black background for the rollout timeline and a photo background for the productivity metric.Hugo Boss | Results Presentation Deck | 44 slides · Hugo Boss
Conference presentation Investor relations 1 hit
17
The slide uses a grid of four black boxes to highlight key performance indicators and strategic pillars.Hugo Boss | Results Presentation Deck | 44 slides · Hugo Boss
Conference presentation Investor relations 1 hit
18
Hugo Boss | Results Presentation Deck | 44 slidesHugo Boss | Results Presentation Deck | 44 slides · Hugo Boss
Conference presentation Investor relations 1 hit
20
The slide uses a gradient bar chart to represent values and a large metric for employee satisfaction.Hugo Boss | Results Presentation Deck | 44 slides · Hugo Boss
Conference presentation Investor relations 1 hit
21
The slide uses a combination of bulleted strategic initiatives and regional performance metrics (sourcing volumes vs. sales).Hugo Boss | Results Presentation Deck | 44 slides · Hugo Boss
Conference presentation Investor relations 1 hit
30
The chart uses a dual-axis approach: bars for absolute EUR million values and a line for percentage of sales.Hugo Boss | Results Presentation Deck | 44 slides · Hugo Boss
Conference presentation Investor relations Beat · SatisfactionLoop · Cost Of Inaction1 hit
34
The slide uses a simple bar chart comparison between 2023 actuals and 2024 estimates.Hugo Boss | Results Presentation Deck | 44 slides · Hugo Boss
Conference presentation Investor relations Beat · Action1 hit
38
The slide uses a high-contrast design with a large brand logo and a background image of a Hugo Boss store installation.Hugo Boss | Results Presentation Deck | 44 slides · Hugo Boss
Conference presentation Investor relations Beat · Action1 hit
39
The chart uses a waterfall bridge to show the path from 61.5% margin to the 62-64% 'Claim 5' ambition range.Hugo Boss | Results Presentation Deck | 44 slides · Hugo Boss
Conference presentation Investor relations Beat · Action1 hit
01
Immix Biopharma | Investor Presentation Deck | 56 slidesImmix Biopharma | Investor Presentation Deck | 56 slides · Immix Biopharma
Pitch deck Investor relations 1 hit
08
The slide uses a comparison framework to contrast standard industry benchmarks with the company's clinical data.Immix Biopharma | Investor Presentation Deck | 56 slides · Immix Biopharma
Pitch deck Investor relations Beat · Solution1 hit
13
Uses a bar chart to compare CRS duration in days across four competitors, with NXC-201 highlighted as significantly lower.Immix Biopharma | Investor Presentation Deck | 56 slides · Immix Biopharma
Pitch deck Investor relations Beat · AgitateLoop · Cost Of Inaction1 hit
16
The chart is a swimmer plot showing patient response duration, with an annotation indicating the target population for future enrollment.Immix Biopharma | Investor Presentation Deck | 56 slides · Immix Biopharma
Pitch deck Investor relations Loop · Quick Win Big Bet1 hit
17
The slide uses a visual comparison between existing standard-of-care treatments (left) and the NXC-201 opportunity (center/right).Immix Biopharma | Investor Presentation Deck | 56 slides · Immix Biopharma
Pitch deck Investor relations Beat · Market SizeLoop · Quick Win Big Bet1 hit
18
N-GENIUS TECHNOLOGY PLATFORM; NEXICART-1 Clinical Trial Data.Immix Biopharma | Investor Presentation Deck | 56 slides · Immix Biopharma
Pitch deck Investor relations Loop · Quick Win Big Bet1 hit
24
Immix Biopharma | Investor Presentation Deck | 56 slidesImmix Biopharma | Investor Presentation Deck | 56 slides · Immix Biopharma
Pitch deck Investor relations 1 hit
32
The slide uses a step-diagram to illustrate dose escalation.Immix Biopharma | Investor Presentation Deck | 56 slides · Immix Biopharma
Pitch deck Investor relations 1 hit
56
Immix Biopharma | Investor Presentation Deck | 56 slidesImmix Biopharma | Investor Presentation Deck | 56 slides · Immix Biopharma
Pitch deck Investor relations 1 hit
05
Includes footnote regarding production capacity limitations.Lion Electric | Investor Presentation Deck | 32 slides · Lion Electric
Pitch deck Investor relations Beat · Market SizeLoop · Quick Win Big Bet1 hit
07
The slide uses a comparison table format to show the status of four vehicle models.Lion Electric | Investor Presentation Deck | 32 slides · Lion Electric
Pitch deck Investor relations Beat · ProductLoop · Quick Win Big Bet1 hit
09
The slide highlights the company's physical infrastructure and production capabilities.Lion Electric | Investor Presentation Deck | 32 slides · Lion Electric
Pitch deck Investor relations Beat · ProductLoop · Quick Win Big Bet1 hit
10
The slide highlights operational status and strategic benefits of the U.S. manufacturing site.Lion Electric | Investor Presentation Deck | 32 slides · Lion Electric
Pitch deck Investor relations Beat · ProductLoop · Quick Win Big Bet1 hit
07
The slide uses a before/after visual comparison of the part structure alongside a bar chart for performance validation.Markforged | Results Presentation Deck | 21 slides · Markforged
Conference presentation Investor relations Beat · Early StrugglesLoop · Before After1 hit
08
The slide uses a hub-and-spoke process flow to explain the platform's value proposition.Markforged | Results Presentation Deck | 21 slides · Markforged
Conference presentation Investor relations Beat · Early StrugglesLoop · Before After1 hit
12
Highlights clinical success in patients who failed or could not tolerate standard azole or IV Amphotericin B therapies.Matinas BioPharma | Investor Presentation Deck | 29 slides · Matinas BioPharma
Pitch deck Investor relations Beat · Evidence & ProofLoop · Cost Of Inaction1 hit
13
Includes a timeline of clinical events and longitudinal charts for Creatinine and Potassium levels.Matinas BioPharma | Investor Presentation Deck | 29 slides · Matinas BioPharma
Pitch deck Investor relations Beat · Evidence & ProofLoop · Cost Of Inaction1 hit
23
Uses a before-after-framing style to contrast healthy vs tumor cell interaction.Matinas BioPharma | Investor Presentation Deck | 29 slides · Matinas BioPharma
Pitch deck Investor relations Loop · Quick Win Big Bet1 hit
25
The slide uses a line chart to show weight loss over 22 days, highlighting that IV-Docetaxel causes significant weight loss (toxicity) while oral LNC-Docetaxel maintains weight similar to control.Matinas BioPharma | Investor Presentation Deck | 29 slides · Matinas BioPharma
Pitch deck Investor relations Loop · Quick Win Big Bet1 hit
26
The slide uses a two-column layout to contrast oncology and inflammation results, followed by a summary box of platform capabilities.Matinas BioPharma | Investor Presentation Deck | 29 slides · Matinas BioPharma
Pitch deck Investor relations Loop · Quick Win Big Bet1 hit
27
The slide uses a three-column icon-based layout to summarize IP and regulatory assets.Matinas BioPharma | Investor Presentation Deck | 29 slides · Matinas BioPharma
Pitch deck Investor relations Loop · Quick Win Big Bet1 hit